Genetic Technologies Limited (GNTLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genetic Technologies Limited (GNTLF) with AI Score 44/100 (Weak). Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools for women's health. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Genetic Technologies Limited (GNTLF) Healthcare & Pipeline Overview
Genetic Technologies Limited, operating in the medical diagnostics sector, provides predictive testing tools, primarily BREVAGenplus, for assessing breast cancer risk. The company targets healthcare professionals in breast health and imaging centers, offering genetic testing services across medical, animal, forensic, and plant applications, with research collaborations enhancing its market reach.
Investment Thesis
Genetic Technologies Limited presents an investment opportunity within the growing molecular diagnostics market, particularly in predictive testing for women's health. The company's BREVAGenplus product and GeneType tests address a critical need for early risk assessment in breast and colorectal cancer. With a market capitalization of $1.34 billion, the company's growth potential is tied to expanding the adoption of its existing tests and successfully developing new risk assessment tools for other diseases. Key catalysts include ongoing research collaborations and potential regulatory approvals for new products. However, the company's negative P/E ratio of -0.45 and a profit margin of -156.8% indicate financial challenges that require careful consideration. Success hinges on achieving profitability through increased sales and efficient cost management.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $1.34B reflecting investor valuation of the company's future potential in the molecular diagnostics market.
- Gross Margin of 50.9% indicating a strong ability to control the direct costs associated with its testing services.
- BREVAGenplus is a clinically validated risk assessment test for non-hereditary breast cancer, providing a key revenue stream.
- Research collaborations with institutions like the University of Melbourne and Memorial Sloan Kettering enhance the company's innovation pipeline.
- Beta of 0.25 suggesting the stock is significantly less volatile than the overall market.
Competitors & Peers
Strengths
- Clinically validated BREVAGenplus test.
- Proprietary GeneType tests.
- Research collaborations with leading institutions.
- Diversified genetic testing services.
Weaknesses
- Negative P/E ratio and profit margin.
- Limited market presence compared to larger competitors.
- Dependence on a few key products.
- OTC market listing.
Catalysts
- Upcoming: Potential regulatory approvals for new diagnostic tests.
- Ongoing: Expansion of the GeneType product line for colorectal cancer.
- Ongoing: Research collaborations with leading institutions.
- Ongoing: Geographic expansion into new markets.
Risks
- Potential: Competition from larger diagnostic companies.
- Potential: Regulatory changes affecting genetic testing.
- Potential: Technological advancements rendering existing tests obsolete.
- Ongoing: Negative P/E ratio and profit margin.
- Ongoing: OTC market listing.
Growth Opportunities
- Expanding the GeneType product line for colorectal cancer represents a significant growth opportunity. With increasing awareness of colorectal cancer screening and the need for personalized risk assessment, Genetic Technologies can leverage its existing platform to capture a larger share of this market. Successful commercialization and adoption by healthcare providers could drive substantial revenue growth. The global colorectal cancer diagnostics market is projected to reach billions of dollars, offering a substantial addressable market.
- Developing and commercializing risk assessment tests for cardiovascular disease presents a major growth avenue. Cardiovascular diseases are a leading cause of death globally, and early risk assessment is crucial for prevention and management. Genetic Technologies can leverage its expertise in genomics to develop innovative tests that identify individuals at high risk. Successful development and adoption of these tests could significantly expand the company's market reach and revenue streams. The cardiovascular diagnostics market represents a multi-billion dollar opportunity.
- Geographic expansion into new markets, particularly in Europe and Asia, offers substantial growth potential. By partnering with local distributors and healthcare providers, Genetic Technologies can introduce its BREVAGenplus and GeneType tests to a broader customer base. Adapting its products and marketing strategies to meet the specific needs of different regions can drive adoption and revenue growth. International expansion requires careful planning and execution, but the potential rewards are significant.
- Leveraging research collaborations to develop new diagnostic tests and improve existing ones is crucial for long-term growth. By partnering with leading research institutions, Genetic Technologies can access cutting-edge technologies and scientific expertise. These collaborations can accelerate the development of innovative tests for a range of diseases, enhancing the company's product portfolio and competitive advantage. Successful research collaborations can also lead to publications and presentations that enhance the company's reputation and credibility.
- Expanding genetic testing services beyond human health into animal, forensic, and plant testing provides diversification and growth opportunities. These markets offer unique applications for genetic testing, such as disease detection in animals, forensic analysis in criminal investigations, and crop improvement in agriculture. By leveraging its expertise in genetic testing, Genetic Technologies can tap into these niche markets and generate additional revenue streams. Diversification can also reduce the company's reliance on the human health market and mitigate risks.
Opportunities
- Expanding the GeneType product line for colorectal cancer.
- Developing risk assessment tests for cardiovascular disease.
- Geographic expansion into new markets.
- Leveraging research collaborations to develop new diagnostic tests.
Threats
- Competition from larger diagnostic companies.
- Regulatory changes affecting genetic testing.
- Technological advancements rendering existing tests obsolete.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Clinically validated BREVAGenplus test provides a competitive advantage in the breast cancer risk assessment market.
- Proprietary GeneType tests offer differentiated solutions for colorectal and breast cancer risk assessment.
- Research collaborations with leading institutions enhance innovation and scientific credibility.
- Diversified genetic testing services across medical, animal, forensic, and plant sectors provide multiple revenue streams.
About GNTLF
Genetic Technologies Limited, founded in 1987 and headquartered in Fitzroy, Australia, is a molecular diagnostics company specializing in predictive testing and assessment tools. The company primarily focuses on women's health, offering products and services to help physicians manage and mitigate health risks. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer, marketed to healthcare professionals, breast health centers, imaging centers, obstetricians, gynecologists, and breast surgeons in both Australia and the United States. Beyond BREVAGenplus, Genetic Technologies offers a range of cancer risk assessment tests under the GeneType brand, including tests for colorectal and breast cancer. The company is also actively developing risk assessment tests for other diseases, including cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma, expanding its portfolio to address a broader spectrum of health concerns. Genetic Technologies also provides genetic testing services across various sectors, including medical, animal, forensic, and plant testing, diversifying its revenue streams and market presence. The company maintains research and collaboration agreements with several institutions, including the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom, to drive innovation and expand its scientific knowledge base.
What They Do
- Develop and market BREVAGenplus, a risk assessment test for non-hereditary breast cancer.
- Offer GeneType tests for colorectal and breast cancer risk assessment.
- Develop risk assessment tests for cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma.
- Provide genetic testing services for medical applications.
- Offer genetic testing services for animal applications.
- Provide genetic testing services for forensic applications.
- Offer genetic testing services for plant testing.
- Engage in research and collaboration agreements with universities and research institutions.
Business Model
- Generate revenue through the sale of BREVAGenplus and GeneType tests to healthcare providers and patients.
- Earn revenue from genetic testing services provided to medical, animal, forensic, and plant sectors.
- Collaborate with research institutions to develop new diagnostic tests and improve existing ones.
- Expand market reach through partnerships with distributors and healthcare providers in different regions.
Industry Context
Genetic Technologies Limited operates in the medical diagnostics and research industry, a sector experiencing growth driven by advancements in genomics and personalized medicine. The market is competitive, with companies like CHIZF, CMOPF, CSPHF, EVOTF, and MRCHF also offering diagnostic solutions. The demand for predictive and personalized healthcare is increasing, fueled by a growing awareness of preventive medicine and the potential for early disease detection. Genetic Technologies is positioned to capitalize on these trends with its focus on risk assessment tests, particularly in women's health. The industry is also subject to regulatory oversight and requires continuous innovation to stay competitive.
Key Customers
- Healthcare professionals, including breast health specialists, imaging centers, obstetricians, gynecologists, and breast surgeons.
- Patients seeking risk assessment for breast and colorectal cancer.
- Medical institutions requiring genetic testing services.
- Animal breeders and veterinarians requiring genetic testing services.
- Forensic laboratories requiring genetic testing services.
- Agricultural companies requiring genetic testing services.
Financials
Chart & Info
Genetic Technologies Limited (GNTLF) stock price: Price data unavailable
Latest News
No recent news available for GNTLF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNTLF.
Price Targets
Wall Street price target analysis for GNTLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNTLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kevin Camilleri
Managing Director
Kevin Camilleri is the Managing Director of Genetic Technologies Limited. His background includes extensive experience in the healthcare and biotechnology sectors. He is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership focuses on driving growth through product innovation, market expansion, and strategic partnerships. He manages a team of 55 employees.
Track Record: Under Kevin Camilleri's leadership, Genetic Technologies Limited has focused on expanding its product portfolio and market reach. Key achievements include the continued commercialization of BREVAGenplus and the development of GeneType tests. The company has also strengthened its research collaborations and expanded its genetic testing services. His tenure has been marked by efforts to improve the company's financial performance and position it for long-term growth.
GNTLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Genetic Technologies Limited may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading can be more speculative. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase investment risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's stock price and trading volume.
- Consult with a financial advisor.
- Understand the risks associated with OTC investments.
- Company has been in operation since 1987.
- Offers clinically validated products like BREVAGenplus.
- Maintains research collaborations with reputable institutions.
- Provides genetic testing services across multiple sectors.
What Investors Ask About Genetic Technologies Limited (GNTLF)
What does Genetic Technologies Limited do?
Genetic Technologies Limited is a molecular diagnostics company focused on providing predictive testing and assessment tools, primarily for women's health. Their main product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. Additionally, they offer GeneType tests for colorectal and breast cancer, and are developing tests for other diseases like cardiovascular disease and type 2 diabetes. The company also provides genetic testing services for medical, animal, forensic, and plant applications, diversifying their revenue streams within the healthcare sector.
What do analysts say about GNTLF stock?
As of March 16, 2026, a comprehensive analyst consensus for Genetic Technologies Limited (GNTLF) is not readily available. However, key valuation metrics to consider include the company's market capitalization of $1.34 billion, a negative P/E ratio of -0.45, and a gross margin of 50.9%. Growth considerations should focus on the company's ability to expand its product portfolio, increase market penetration, and achieve profitability. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for GNTLF?
The main risks for Genetic Technologies Limited include intense competition from larger diagnostic companies, potential regulatory changes impacting genetic testing, and the risk of technological advancements rendering their existing tests obsolete. The company's negative P/E ratio and profit margin also pose financial risks. Furthermore, being listed on the OTC market introduces additional risks related to liquidity, volatility, and limited disclosure. Investors should carefully consider these risks before investing in GNTLF.
What are the key factors to evaluate for GNTLF?
Genetic Technologies Limited (GNTLF) currently holds an AI score of 44/100, indicating low score. Key strength: Clinically validated BREVAGenplus test.. Primary risk to monitor: Potential: Competition from larger diagnostic companies.. This is not financial advice.
How frequently does GNTLF data refresh on this page?
GNTLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNTLF's recent stock price performance?
Recent price movement in Genetic Technologies Limited (GNTLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Clinically validated BREVAGenplus test.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNTLF overvalued or undervalued right now?
Determining whether Genetic Technologies Limited (GNTLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNTLF?
Before investing in Genetic Technologies Limited (GNTLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- AI analysis is pending for GNTLF.